Abstract Body

Fecal calprotectin (FCP), a biomarker of gastrointestinal inflammation, is used in the diagnosis and management of inflammatory bowel disease. HIV infection severely damages gut-associated lymphoid and epithelial tissues leading to gut inflammation, microbial translocation and systemic inflammation/immune activation. We sought to investigate FCP in people with HIV (PWH) for the first time and determine its relationship to HIV-specific factors and systemic inflammation/immune activation.

PWH naïve to ART, ART-treated and uninfected controls were prospectively enrolled. Stool samples were collected and FCP was measured by ELISA. Plasma biomarkers of inflammation/immune activation were also measured. FCP was evaluated as a continuous variable and by thresholds. Spearman correlations were used to investigate associations with FCP.

101 PWH (83 ART-treated, 18 naïve) and 89 uninfected controls were enrolled. ART-treated were older than naïve (51 vs 31 yrs; P=0.006), but sex and race were similar (overall 78% males, 66% blacks). All but one ART-treated had HIV RNA <200 copies/mL. CD4 counts for treated and naïve were 683 and 410 cells/µL, resp. Controls had a median age of 37 yrs (78% males, 22% blacks). There was a difference (P=0.001) in FCP among the 3 groups with the highest median (25th, 75th %ile) FCP in ART-naïve [144 (33, 262) µg/g] followed by ART-treated [78 (36, 141) µg/g] and then controls [41 (21, 89) µg/g] (Fig). 56% of ART-naïve had FCP >100 µg/g vs 37% in treated and 19% in controls (P=0.0003). In PWH, high-sensitivity C-reactive protein (R=0.30; P=0.008), soluble tumor necrosis factor-II (R=0.28; P=0.006), and soluble vascular cellular adhesion molecule (R=0.21; P=0.04) were positively associated with FCP. Interleukin-6 (R=0.29; P=0.01) and soluble CD163 (R=0.54; P=0.04) were also positively associated with FCP in treated and naïve, resp. FCP was inversely associated with CD4 (R=-0.24; P=0.02), but not with other HIV variables, nor age, sex, or race.

Stool concentrations of FCP are elevated in PWH. ART appears to reduce FCP but not to concentrations seen in uninfected controls. FCP concentrations are positively correlated with several markers of systemic inflammation/immune activation, and negatively with CD4. FCP may serve as a useful biomarker to monitor gastrointestinal inflammation and associated systemic inflammation/immune activation in HIV.